Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Jurnal Bioteknologi & Biosains Indonesia
Darmayanti, Salma
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
LIPID PRODUCTION FROM BR. 2.2 OLEAGINOUS FUNGAL ISOLATE USING ACETATE, GLYCEROL, AND MOLASSES AS CARBON SOURCES Alifiyatin, Chikmatul; Darmayanti, Salma; Firdasi, Wanny; Ilmi, Miftahul
Jurnal Bioteknologi & Biosains Indonesia (JBBI) Vol. 10 No. 1 (2023)
Publisher : BRIN - Badan Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/jbbi.2023.1745

Abstract

Microorganisms that accumulate more than 20% of their dry cell weight as lipids are called oleaginous microorganisms. Oleaginous microorganisms can grow well on various carbon sources other than glucose. These non-glucose alternative carbon sources could potentially reduce high biofuel manufacturing costs. BR. 2.2 isolate is an oleaginous fungus that accumulates 0.62 g L-1 lipids using glucose as a carbon source. This study aims to determine the effect of acetate, glycerol, molasses, and C/N ratios on lipid accumulation of the BR.2.2 isolate. The highest lipid produced by the BR. 2.2 isolate using acetate is 0.196 g L-1 at a C/N ratio of 400, 0.229 g L-1 at a C/N ratio of 225 using glycerol, and 1.97 g L-1 at a C/N ratio of 25 using molasses in 144 hours of incubation. The results revealed that the accumulation of lipids increased with the rising acetate and glycerol C/ N ratios and incubation period. Meanwhile, the accumulation of lipids decreased with increasing molasses C/N ratio.
The Potential of Lasofoxifene as a New Hormone Therapy Targeting ESR1 Mutations in ER+ Breast Cancer Patients: A Narrative Review Abidin Shahab, Ali Zainal; Darmayanti, Salma
Indonesian Journal of Cancer Vol 20, No 1 (2026): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i1.1423

Abstract

Breast cancer remains the most prevalent malignancy among women and a leading cause of cancer-related mortality worldwide. Estrogen receptor-positive (ER+) breast cancer accounts for the majority of breast cancer cases, with hormonal therapy being the primary treatment approach. However, resistance to conventional endocrine therapy, particularly due to mutations in the estrogen receptor 1 (ESR1) gene, poses a significant challenge. ESR1 mutations, especially in the ligand-binding domain, lead to ligand-independent activation of the receptor, rendering standard therapies ineffective. Lasofoxifene, a selective estrogen receptor modulator (SERM), has emerged as a promising alternative for ER+ breast cancer patients with ESR1 mutations. Preclinical studies have demonstrated its ability to inhibit tumor growth and metastasis more effectively than current endocrine therapies. Moreover, clinical trials, such as ELAINE 1 and ELAINE 2, have shown promising outcomes, particularly in combination with CDK4/6 inhibitors, suggesting improved progression-free survival and clinical benefit rates. Lasofoxifene's unique pharmacological profile allows it to stabilize both wild-type and mutant ESR1 receptors, making it a potential targeted therapy for hormone-resistant breast cancer. Despite its potential, several challenges remain, including the risk of drug resistance and the need for further clinical validation. Future research should focus on optimizing combination therapies, understanding resistance mechanisms, and identifying predictive biomarkers to personalize treatment strategies. Lasofoxifene represents a novel therapeutic avenue in the management of ER+ breast cancer, offering hope for patients with limited treatment options due to endocrine therapy resistance.
Co-Authors Abidin Shahab, Ali Zainal Alifiyatin, Chikmatul Firdasi, Wanny Miftahul Ilmi, Miftahul